Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.clgc.2023.01.001
PubMed Identifier: 36697317
Publication URI: http://europepmc.org/abstract/MED/36697317
Type: Journal Article/Review
Volume: 21
Parent Publication: Clinical genitourinary cancer
Issue: 2
ISSN: 1558-7673